Read more

August 31, 2020
1 min read
Save

Superior capsular reconstruction may be an option for irreparable supraspinatus tears

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Arthroscopic superior capsular reconstruction may offer a short-term bridging option for young, active patients with irreparable supraspinatus tears, according to published results.

From April 2015 to April 2017, researchers performed a retrospective consecutive case series on 25 patients who underwent arthroscopic superior capsular reconstruction (SCR) with dermal allograft. The researchers analyzed patients for 2-year clinical outcomes. All procedures were done by a single surgeon at a single center, according to the study. Outcome measures included Oxford Shoulder Score, range of motion, patient satisfaction and MRI data.

At 1-year follow-up, researchers found successful outcomes in 20 patients (80%) and 18 patients (72%) at 2-year follow-up.

“The mean Oxford Shoulder Score improved by a minimum of 10 points at all time points compared with preoperatively. The mean forward flexion and abduction improved by 20° and external rotation by 7°,” the researchers wrote in the study. “Revision to reverse shoulder arthroplasty was seen in three patients (12%). Graft failure was seen in four patients (16%),” they added.

The researchers concluded that SCR offers a safe and effective option for the short-term treatment of irreparable supraspinatus tears in the absence of glenohumeral joint arthritis. Yet, the cost-effectiveness and long-term outcomes of the procedure remain unknown, they wrote.

“Several concerns are consistently raised, including optimal graft thickness, graft type, graft healing and longer-term clinical outcomes,” they wrote. “Randomized controlled trials comparing SCR with other treatment options (eg, debridement alone, margin convergence, or placebo) are required to justify the cost-effectiveness,” they added.